Raymond James raised the firm’s price target on ICU Medical to $158 from $135 and keeps an Outperform rating on the shares. ICU Medical reported “exceptional” Q2 results, beating on every key metric, the analyst tells investors in a research note. The firm is not modeling this level of growth going forward, but says the business is clearly gaining momentum and the raised guidance should prove conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI:
Questions or Comments about the article? Write to editor@tipranks.com